Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCreo Medical Regulatory News (CREO)

Share Price Information for Creo Medical (CREO)

Share Price is delayed by 15 minutes
Get Live Data
13.50    0.00 (0.00%)
Bid:
13.25
Ask:
13.75
Spread: 0.50 (3.774%)
Market Cap: £65.58m
CREO Live PriceLast checked at - London Stock Exchange

Intraday Creo Medical Share Chart

Proposed Acquisition

14 Dec 2006 09:17

China Real Estate Opportunities SA14 December 2006 CHINA REAL ESTATE OPPORTUNITIES S.A. PROPOSED ACQUISITION OF BEIJING PROPERTY China Real Estate Opportunities S.A. ("CREO") announces that it has todayexchanged conditional contracts for the acquisition of a property in Beijing,China. The property is a prime mixed-use development located in central Beijing, knownas the Xidan Centrepoint Shopping Centre, Office Complex and Hotel. CREO hascommitted to purchase 100% of the property subject to a number of conditionsincluding the construction of the project being substantially complete and CREOshareholder approval. The vendor is a wholly-owned subsidiary of ChinaMetallurgical Construction (Group) Corp, one of China's largest conglomeratesand a company controlled by China's central government. Xidan Centrepoint is located in a prime location on one of Beijing's busiestshopping and commercial streets, known as Xidan. The street runs north-southapproximately 1km directly west of the Forbidden City and Tiananmen Square andapproximately 1km directly to the east of the Financial Street district. Theproperty lies less than 100 metres north of Xidan (underground) Station. The property covers a site area of 16,073 square metres and will when completehave a total gross built floor area of approximately 194,949 square metres over15 floors above ground and 4 floors below ground. Of this area, approximately102,945 square metres is designated for retail, a 372 room luxury hotelcomponent comprises another 32,126 square metres, while an office component is afurther 15,858 square metres. 1,000 car parking spaces and ancillary uses aredesignated for the remaining 44,020 square metres. The property is currently under construction and is expected to be completed byDecember 2007. CREO has agreed to pay a total price of RMB 3,742,520,000(approximately £243.1m or €361.9m*) payable in stages as title to the propertyis acquired and as the property is completed and leased out. An initial depositwill be paid by the Company from existing cash resources amounting to RMB187,876,000 (£12.2 million or €18.2 million). Since this acquisition will be a reverse takeover under the AIM rules, pendingshareholder approval and completion of the acquisition, the shares of theCompany were suspended from trading on AIM with effect from 10.00 a.m. on 8thDecember at the request of the Company. A circular will be sent to CREO shareholders in due course detailing the termsof the proposed acquisition along with an admission document. It is expectedthat the shares in CREO will remain suspended until the acquisition has beenapproved. CREO will be undertaking a fund raising in the New Year by way of aplacing of new shares to the market and a further announcement regarding thiswill be made in due course CREO is majority owned by the directors of Treasury Holdings ("Treasury"), RealEstate Opportunities Ltd ("REO") and the directors of REO. It will be proposedin the forthcoming circular that CREO will be managed by Treasury, Ireland'slargest property developer. Treasury owns 58.5% of REO's ordinary shares. Treasury controls a large property investment and development portfolio acrossEurope as well as very substantial interests in environmental technology,renewable energy and waste management. Treasury started operations in China in2002 working with Shanghai Industrial Investment Company, a company owned by theShanghai Municipal Government, on the development of the Chongming Eco City justoutside Shanghai. Since then, Treasury has expanded its business considerablyboth in Shanghai and Beijing and 3 of the 6 executive main Board Treasurydirectors are now resident in China to grow the business. CREO was formed in December 2005 to investigate real estate opportunities inChina. *Exchange rate £1:RMB 15.39, €1 EUR:RMB 10.34 Enquiries to: CREORay Horney, Chairman Tel: +44 (0) 1273 775225 Treasury HoldingsRob Tincknell Tel: + 86 137 889 83016 (N.B GMT + 8hrs) Teather & GreenwoodPaul Fincham Tel: +44 (0)20 7426 7736 Bankside Consultants (UK)Simon RothschildOliver Winters Tel: +44 (0)20 7367 8888 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
23rd Jun 20267:00 amRNSAppointment of Nominated Adviser /Corporate Broker
4th Jun 20267:00 amRNSPosting of 2025 Annual Report and Notice of AGM
28th May 20262:35 pmRNSHolding(s) in Company
22nd May 202610:11 amRNSResult of Placing
22nd May 20267:02 amRNSProposed Placing to raise approximately £5.5m
22nd May 20267:01 amRNSFY25 Final Results
22nd May 20267:00 amRNSProposed Sale of 49% Interest in Creo Medical SL
7th May 20267:00 amRNS-RMicroBlate™ Fine commercial update
5th May 20267:00 amRNS-RSpydrBlade™ Flex used in novel BEAM procedures
30th Apr 20267:00 amRNS-RKOL presentations on Creo Core Products at DDW
29th Apr 20267:00 amRNS-RUK private hospital use Speedboat for cancer case
22nd Apr 20267:00 amRNSPositive Q1 trading update
16th Apr 20267:00 amRNSDisposal and outsourcing of manufacturing
24th Feb 20267:00 amRNSAppointment of Joint Corporate Broker
20th Jan 20267:00 amRNSFY25 Trading Update
14th Jan 20267:00 amRNSAward of Shares under Share Incentive Plan
27th Oct 20257:00 amRNSNotice of Capital Markets Day
7th Oct 202511:37 amRNSCapital Markets Day update
22nd Sep 20257:00 amRNSUnaudited results for the six months ended 30 June
12th Sep 20253:14 pmRNSHolding(s) in Company
11th Sep 20257:00 amRNSNotice of Results
12th Aug 20254:56 pmRNSDirector/PDMR Share Dealing
4th Aug 20257:00 amRNS-RSpeedboat® patient testimonial
24th Jul 20257:00 amRNSAward of Shares under SIP and Director Dealings
21st Jul 20257:00 amRNSH1’25 Trading Update
10th Jul 20257:00 amRNS-RMicroBlate™ Flex begins lung tumour clinical study
9th Jul 20259:41 amRNSPDMR Options Revision
30th Jun 20257:00 amRNSChange of Nominated Adviser
26th Jun 202511:08 amRNSResult of AGM
26th Jun 20257:00 amRNSAGM Statement and Directorate Changes
11th Jun 20257:00 amRNS-RU.S. FDA clearance for SpydrBlade™ Flex
2nd Jun 20257:00 amRNSDirector/PDMR Shareholding
30th May 20257:00 amRNSPosting of AR&R and Notice of AGM
28th May 20257:00 amRNSUS Reimbursement milestone for Speedboat procedure
27th May 202512:48 pmRNSHolding(s) in Company
23rd May 20254:25 pmRNSHolding(s) in Company
22nd May 20257:00 amRNSDirectorate changes
19th May 20257:00 amRNSFinal Results
6th May 20257:00 amRNSNotice of investor presentations
15th Apr 20252:00 pmRNSNotice of Results
1st Apr 20259:34 amRNSHolding(s) in Company
31st Mar 202512:17 pmRNSHolding(s) in Company
26th Mar 20257:00 amRNSGrant of Options
20th Mar 20257:00 amRNS-RUK & EU Commercial launch of SpydrBlade™ Flex
6th Mar 20257:00 amRNSAppointment of Nominated Adviser and sole Broker
17th Feb 20257:00 amRNSFY24 Trading Update
12th Feb 202511:00 amRNSCompletion of sale of 51% interest in subsidiary
6th Feb 20259:00 amRNS-RFirst Welsh adopter of Speedboat® technology
3rd Feb 20253:00 pmRNSTotal Voting Rights
21st Jan 20257:00 amRNSAward of Shares under Share Incentive Plan

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.